Aethlon Medical advances Hemopurifier study as final trial cohort nears completion

Aethlon Medical CEO James Frakes joined Steve Darling from Proactive to discuss the company’s Hemopurifier® technology and the progress of its ongoing clinical program evaluating the device’s potential role in cancer treatment. The Hemopurifier is an investigational medical device designed to remove harmful particles from the bloodstream. Frakes explained that the technology works alongside existing dialysis and blood-pumping systems, using a plant lectin-based mechanism to bind and remove viruses as well as cancer-associated extracellular vesicles (EVs), which are believed to play a role in tumor growth, immune suppression, and the spread of cancer. Aethlon has received two FDA Breakthrough Device Designations, one targeting life-threatening viral infections with no approved treatments and another focused on oncology applications. While the company initially concentrated on infectious diseases such as Ebola, Frakes said its primary development focus has now shifted toward cancer treatment. A key area of interest is the company’s ongoing safety study in Australia, which is now more than two-thirds complete. The trial is investigating whether removing cancer-associated EVs from the bloodstream can help restore immune system function and potentially reduce metastatic disease progression. “The concept is removing these EVs helps the body fight against metastasis, the spread of cancer,” Frakes said. The study consists of three cohorts evaluating increasing treatment frequency. The first two cohorts have been completed, while enrollment and treatment in the third cohort are currently underway. Researchers are also analyzing changes in EV levels and immune system biomarkers with laboratory support from the University of Sydney. Frakes said Aethlon expects to complete the final cohort during the summer, followed by data analysis and regulatory submissions in Australia and the United States later in 2026. Management believes the results could provide important insights into the potential of Hemopurifier as a novel adjunct therapy in oncology. #proactiveinvestors #aethlonmedical #nasdaq #aemd #medicaltherapeutics #Hemopurifier #CancerResearch #Oncology #Biotech #MedicalDevices #ClinicalTrials #HealthcareInnovation #Immunotherapy #CancerTreatment